At ViiV Healthcare, our goal is simple: to end the HIV epidemic. Over the last 40 years, there have been incredible advances in the development of effective HIV treatments that allow people living with HIV to suppress their virus to undetectable levels.
However, the needs of people living with HIV change over time, and we‘re exploring new ways of treating and preventing HIV through new mechanisms of action and drug delivery.
We have a number of potential medicines in development for the treatment and prevention of HIV.
Clinical development pipeline
Compound number / Generic name / Brand name |
Indication |
Phase |
Mode of action / Vaccine type |
|---|---|---|---|
| VH3810109 ✝ | HIV |
Phase II |
HIV broadly neutralising antibody |
| VH4011499 | HIV | Phase II | HIV capsid protein inhibitor |
| VH4524184 ✝ | HIV | Phase II | HIV integrase inhibitor |
| GSK1265744 cabotegravir |
HIV | Phase I | HIV integrase inhibitor |
✝In-license or other alliance relationship with third party
RELATED TOPICS
Since the advent of highly active antiretroviral therapy HIV has become a long-term health condition, as many people living with HIV with access to treatment are now living longer, healthier lives than before. However, Positive Perspectives study results indicate that many people living with HIV still aspire to treatments that have even less impact on quality of life.
Discover how we work with leading researchers and academic groups to innovate and bring the best science to HIV treatment, prevention and care.
With significant progress made in the fight against HIV, how do we make sure that clinically proven tools are implemented into real-world settings?
